Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

NCT03409198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Hormone Receptor Positive Tumor
Metastatic Breast Cancer

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Pegylated liposomal doxorubicin
DRUG: Cyclophosphamide

Sponsor

Oslo University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]